

**Clinical trial results:****A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype**

Due to a system error, the data reported in v1 is not correct and has been removed from public view.

Summary

EudraCT number	2011-001323-21
Trial protocol	DE AT PL
Global end of trial date	13 January 2014

Results information

Result version number	v2 (current)
This version publication date	13 July 2016
First version publication date	07 August 2015
Version creation reason	<ul style="list-style-type: none">• Correction of full data set Update required to address issues related to the EudraCT System bug, that necessitated the review and Quality check of results posting and to ensure data accuracy

Trial information**Trial identification**

Sponsor protocol code	VX11-950-114
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01459913
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Vertex Pharmaceuticals Incorporated
Sponsor organisation address	50 Northern Avenue, Boston, Massachusetts, United States, 02210-1862
Public contact	Medical Monitor, Vertex Pharmaceuticals Incorporated, 1 617-341-6777, medicalinfo@vrtx.com
Scientific contact	Medical Monitor, Vertex Pharmaceuticals Incorporated, 1 617-341-6777, medicalinfo@vrtx.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 February 2014
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	13 January 2014
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy of a 12-week regimen of telaprevir, pegylated interferon (Peg-IFN), and ribavirin (RBV) in treatment-naive and prior relapser subjects with genotype 1 chronic hepatitis C (CHC) and interleukin-28B (IL28B) CC genotype

Protection of trial subjects:

The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Conference on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	11 November 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 25
Country: Number of subjects enrolled	Germany: 11
Country: Number of subjects enrolled	Canada: 28
Country: Number of subjects enrolled	Poland: 19
Country: Number of subjects enrolled	Israel: 18
Country: Number of subjects enrolled	United States: 138
Worldwide total number of subjects	239
EEA total number of subjects	55

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	228
From 65 to 84 years	11
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Subjects received telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a)/ ribavirin (RBV). Planned duration of telaprevir treatment was 12 weeks. Minimum planned duration of Peg-IFN-alfa-2a/RBV treatment was 12 weeks; however, was dependent on virologic response during initial 12 weeks of telaprevir plus Peg-IFN-alfa-2a/RBV.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)

Arm description:

Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met rapid viral response (RVR, undetectable Hepatitis C Virus [HCV] Ribonucleic Acid [RNA] at Week 4) criteria, were randomized in this group, as planned, and did not receive any further treatment.

Arm type	Experimental
Investigational medicinal product name	Telaprevir
Investigational medicinal product code	VX-950
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks.

Investigational medicinal product name	Pegylated interferon alfa 2a
Investigational medicinal product code	
Other name	Pegasys ®, Peg-INF
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week).

Investigational medicinal product name	Ribavirin
Investigational medicinal product code	
Other name	Copegus ®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Ribavirin (RBV) tablet twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 12 weeks.

Arm title	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)
------------------	---

Arm description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.

Arm type	Experimental
Investigational medicinal product name	Telaprevir
Investigational medicinal product code	VX-950
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Telaprevir 1125 mg tablet twice daily for 12 weeks.

Investigational medicinal product name	Peg-IFN-alfa-2a
Investigational medicinal product code	
Other name	Pegasys ®, Peg-INF
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Peg-IFN-alfa-2a 180 mcg/week.

Investigational medicinal product name	Ribavirin
Investigational medicinal product code	
Other name	Copegus ®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

RBV tablet twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks.

Arm title	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)
------------------	---

Arm description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.

Arm type	Experimental
Investigational medicinal product name	Telaprevir
Investigational medicinal product code	VX-950
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Telaprevir 1125 mg tablet twice daily for 12 weeks.

Investigational medicinal product name	Pegylated interferon alfa 2a
Investigational medicinal product code	
Other name	Pegasys ®, Peg-INF
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Peg-IFN-alfa-2a 180 mcg/week .

Investigational medicinal product name	Ribavirin
Investigational medicinal product code	
Other name	Copegus ®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

RBV tablet twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 24 weeks.

Arm title	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)
------------------	---

Arm description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.

Arm type	Experimental
Investigational medicinal product name	Telaprevir
Investigational medicinal product code	VX-950
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Telaprevir 1125 mg tablet twice daily for 12 weeks.

Investigational medicinal product name	Pegylated interferon alfa 2a
Investigational medicinal product code	
Other name	Pegasys ®, Peg-INF
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Peg-IFN-alfa-2a 180 mcg/week.

Investigational medicinal product name	Ribavirin
Investigational medicinal product code	
Other name	Copegus ®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

RBV tablet twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 48 weeks.

Number of subjects in period 1	Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)
Started	106	52	19
Completed	65	32	6
Not completed	41	20	13
Consent withdrawn by subject	4	-	-
Physician decision	-	1	-
Adverse Event	-	-	-

Death	-	-	-
Did Not Meet Inclusion Criteria	-	-	-
Unspecified	-	-	3
Study Terminated by Sponsor	30	15	9
Lost to follow-up	7	4	1
Non- Compliance	-	-	-

Number of subjects in period 1	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)
Started	62
Completed	29
Not completed	33
Consent withdrawn by subject	5
Physician decision	-
Adverse Event	3
Death	1
Did Not Meet Inclusion Criteria	1
Unspecified	1
Study Terminated by Sponsor	11
Lost to follow-up	8
Non- Compliance	3

Baseline characteristics

Reporting groups

Reporting group title	Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)
-----------------------	--

Reporting group description:

Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met rapid viral response (RVR, undetectable Hepatitis C Virus [HCV] Ribonucleic Acid [RNA] at Week 4) criteria, were randomized in this group, as planned, and did not receive any further treatment.

Reporting group title	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)
-----------------------	---

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.

Reporting group title	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)
-----------------------	---

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.

Reporting group title	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)
-----------------------	---

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.

Reporting group values	Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)
Number of subjects	106	52	19
Age categorical Units: Subjects			
Age continuous			
Number subjects analysed for this parameter are 106, 52, 19 and 61 respectively.			
Units: years			
arithmetic mean	46.1	44.8	54.4
standard deviation	± 12.82	± 12.89	± 8.7
Gender categorical Units: Subjects			
Female	39	16	11
Male	67	36	8

Reporting group values	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)	Total	
Number of subjects	62	239	
Age categorical Units: Subjects			
Age continuous			
Number subjects analysed for this parameter are 106, 52, 19 and 61 respectively.			
Units: years arithmetic mean standard deviation	49.8 ± 10.56	-	
Gender categorical Units: Subjects			
Female	29	95	
Male	33	144	

End points

End points reporting groups

Reporting group title	Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)
-----------------------	--

Reporting group description:

Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met rapid viral response (RVR, undetectable Hepatitis C Virus [HCV] Ribonucleic Acid [RNA] at Week 4) criteria, were randomized in this group, as planned, and did not receive any further treatment.

Reporting group title	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)
-----------------------	---

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.

Reporting group title	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)
-----------------------	---

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.

Reporting group title	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)
-----------------------	---

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.

Subject analysis set title	Telaprevir+Peg-IFN-alfa-2a, RBV (Total)
----------------------------	---

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

All subjects who received telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, up to 48 weeks.

Primary: Percentage of Subjects With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)

End point title	Percentage of Subjects With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12) ^{[1][2]}
-----------------	---

End point description:

SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 12 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. Full Analysis (FA) Set was used.

End point type	Primary
----------------	---------

End point timeframe:

12 weeks after last planned dose of study drug (up to Week 36)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No inferential statistics was planned for this study.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

End point values	Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	106	52		
Units: Percentage of Subjects				
number (not applicable)	88.7	96.2		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)

End point title	Percentage of Subjects With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4) ^[3]
-----------------	--

End point description:

SVR4 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 4 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. FA Set was used.

End point type	Secondary
----------------	-----------

End point timeframe:

4 weeks after last planned dose of study drug (up to Week 28)

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

End point values	Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	106	52		
Units: Percentage of Subjects				
number (not applicable)	89.6	98.1		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)

End point title	Percentage of Subjects With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24) ^[4]
-----------------	--

End point description:

SVR24 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 24 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. FA Set was used.

End point type	Secondary
----------------	-----------

End point timeframe:

24 weeks after last planned dose of study drug (up to Week 48)

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

End point values	Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	106	52		
Units: Percentage of Subjects				
number (not applicable)	85.8	92.3		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Sustained Viral Response at Week 72 (SVR72)

End point title	Percentage of Subjects With Sustained Viral Response at Week 72 (SVR72) ^[5]
-----------------	--

End point description:

SVR72 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Week 72. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. FA Set was used. Here number of subjects analyzed = subjects who were evaluable for this measure. Subjects who did not have the SVR72 assessment because they discontinued the study due to 'Study Terminated by the Sponsor' are excluded from this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 72

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)"

reporting groups.

End point values	Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	76	37		
Units: Percentage of Subjects				
number (not applicable)	72.4	86.5		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Viral Relapse

End point title	Percentage of Subjects With Viral Relapse ^[6]
End point description:	
Viral relapse was defined as having detectable HCV RNA during antiviral follow-up in subjects who had HCV RNA less than (<) lower limit of quantification (LLOQ) at end of treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The LLOQ was 25 IU/mL and the lower limit of detection was 10 IU/mL. FA Set was used.	
End point type	Secondary
End point timeframe:	
After last dose of study drug up to 4 weeks (up to Week 28), 12 weeks (up to Week 36), 24 weeks (up to Week 48) antiviral follow-up	

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

End point values	Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	106	52		
Units: Percentage of Subjects				
number (not applicable)				
4 Weeks	1.9	0		
12 Weeks	7.5	0		
24 Weeks	10.4	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With On-Treatment Virologic Failure

End point title | Percentage of Subjects With On-Treatment Virologic Failure

End point description:

On-treatment virologic failure was defined as subjects who met futility (as per investigator discretion) or who completed the assigned treatment duration and had detectable HCV RNA at planned end of treatment (up to 48 weeks). This outcome was planned to be assessed in all reporting groups and results were to be reported for total arm as well. FA Set was used.

End point type | Secondary

End point timeframe:

Baseline up to Week 48

End point values	Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	52	19	61
Units: Percentage of Subjects				
number (not applicable)	0	0	0	3.3

End point values	Telaprevir+Peg-IFN-alfa-2a, RBV (Total)			
Subject group type	Subject analysis set			
Number of subjects analysed	238			
Units: Percentage of Subjects				
number (not applicable)	0.8			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Rapid Viral Response (RVR)

End point title | Number of Subjects With Rapid Viral Response (RVR)^[7]

End point description:

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment. FA Set was used.

End point type | Secondary

End point timeframe:

Week 4

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

End point values	Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	106	52		
Units: Subjects	106	52		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Extended Rapid Viral Response (eRVR)

End point title	Number of Subjects With Extended Rapid Viral Response (eRVR) ^[8]
-----------------	---

End point description:

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. eRVR was defined as undetectable HCV RNA at both 4 weeks and 12 weeks after the start of study treatment. FA Set was used.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 4 and Week 12

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

End point values	Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	106	52		
Units: Subjects	105	51		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Adverse Events (AEs) and Serious Adverse

Events (SAEs)

End point title	Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
End point description: AE: any adverse change from the subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. "Study drug" includes all investigational agents administered during the course of the study. Safety set included all subjects who received at least 1 dose of study drug.	
End point type	Secondary
End point timeframe: Baseline up to Week 48	

End point values	Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	106	52	19	62
Units: Subjects				
AEs	104	51	19	61
SAEs	5	4	3	13

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to Week 48

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.1
--------------------	------

Reporting groups

Reporting group title	Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)
-----------------------	---

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned, and did not receive any further treatment.

Reporting group title	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)
-----------------------	---

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.

Reporting group title	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)
-----------------------	---

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.

Reporting group title	Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)
-----------------------	--

Reporting group description:

Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.

Serious adverse events	Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 106 (4.72%)	4 / 52 (7.69%)	3 / 19 (15.79%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			

Alcohol poisoning			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Syncope			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 106 (1.89%)	3 / 52 (5.77%)	2 / 19 (10.53%)
occurrences causally related to treatment / all	3 / 3	3 / 3	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			

subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis microscopic			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis chronic			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Hypoxia			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Skin and subcutaneous tissue disorders Drug reaction with eosinophilia and systemic symptoms subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 106 (0.00%) 0 / 0 0 / 0	0 / 52 (0.00%) 0 / 0 0 / 0	0 / 19 (0.00%) 0 / 0 0 / 0
Psychiatric disorders Anxiety subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 106 (0.94%) 0 / 1 0 / 0	0 / 52 (0.00%) 0 / 0 0 / 0	0 / 19 (0.00%) 0 / 0 0 / 0
Renal and urinary disorders Renal failure acute subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 106 (0.00%) 0 / 0 0 / 0	0 / 52 (0.00%) 0 / 0 0 / 0	0 / 19 (0.00%) 0 / 0 0 / 0
Infections and infestations Pneumonia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 106 (0.00%) 0 / 0 0 / 0	0 / 52 (0.00%) 0 / 0 0 / 0	0 / 19 (0.00%) 0 / 0 0 / 0
Abscess oral subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 106 (0.00%) 0 / 0 0 / 0	0 / 52 (0.00%) 0 / 0 0 / 0	1 / 19 (5.26%) 0 / 1 0 / 0
Bacteraemia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 106 (0.00%) 0 / 0 0 / 0	0 / 52 (0.00%) 0 / 0 0 / 0	1 / 19 (5.26%) 1 / 1 0 / 0
Perirectal abscess subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 106 (0.00%) 0 / 0 0 / 0	1 / 52 (1.92%) 0 / 1 0 / 0	0 / 19 (0.00%) 0 / 0 0 / 0

Serious adverse events	Telaprevir 12 Wk +Peg-IFN-alfa- 2a,RBV 48 Wk (Non		
-------------------------------	---	--	--

	Randomized)		
Total subjects affected by serious adverse events			
subjects affected / exposed	13 / 62 (20.97%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Thrombosis			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Syncope			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	7 / 62 (11.29%)		
occurrences causally related to treatment / all	7 / 7		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Asthenia			

subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Chest pain			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Fatigue			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Colitis microscopic			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatitis			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis chronic			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Hypoxia			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Pulmonary embolism			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Drug reaction with eosinophilia and systemic symptoms			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Renal failure acute			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Pneumonia			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
Abscess oral			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bacteraemia			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Perirectal abscess			

subjects affected / exposed	0 / 62 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)	Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	104 / 106 (98.11%)	51 / 52 (98.08%)	19 / 19 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant melanoma			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	2	0
Melanocytic naevus			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Vascular disorders			
Pallor			
subjects affected / exposed	2 / 106 (1.89%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Circulatory collapse			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	2 / 106 (1.89%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Hypertension			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Hypotension			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Orthostatic hypotension			

subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Haematoma			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Orthostatic hypertension			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Peripheral coldness			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Vascular pain			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	55 / 106 (51.89%)	25 / 52 (48.08%)	12 / 19 (63.16%)
occurrences (all)	59	25	13
Pyrexia			
subjects affected / exposed	26 / 106 (24.53%)	13 / 52 (25.00%)	4 / 19 (21.05%)
occurrences (all)	28	14	4
Influenza like illness			
subjects affected / exposed	28 / 106 (26.42%)	10 / 52 (19.23%)	8 / 19 (42.11%)
occurrences (all)	29	10	8
Asthenia			
subjects affected / exposed	14 / 106 (13.21%)	8 / 52 (15.38%)	3 / 19 (15.79%)
occurrences (all)	14	9	3
Irritability			
subjects affected / exposed	9 / 106 (8.49%)	7 / 52 (13.46%)	2 / 19 (10.53%)
occurrences (all)	9	8	2
Chills			
subjects affected / exposed	6 / 106 (5.66%)	6 / 52 (11.54%)	0 / 19 (0.00%)
occurrences (all)	6	6	0
Injection site erythema			

subjects affected / exposed	5 / 106 (4.72%)	4 / 52 (7.69%)	0 / 19 (0.00%)
occurrences (all)	5	4	0
Pain			
subjects affected / exposed	5 / 106 (4.72%)	3 / 52 (5.77%)	1 / 19 (5.26%)
occurrences (all)	5	3	1
Malaise			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
Oedema peripheral			
subjects affected / exposed	1 / 106 (0.94%)	4 / 52 (7.69%)	1 / 19 (5.26%)
occurrences (all)	1	4	1
Injection site reaction			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Chest pain			
subjects affected / exposed	2 / 106 (1.89%)	2 / 52 (3.85%)	1 / 19 (5.26%)
occurrences (all)	2	2	1
Injection site rash			
subjects affected / exposed	1 / 106 (0.94%)	2 / 52 (3.85%)	0 / 19 (0.00%)
occurrences (all)	1	2	0
Chest discomfort			
subjects affected / exposed	0 / 106 (0.00%)	4 / 52 (7.69%)	0 / 19 (0.00%)
occurrences (all)	0	4	0
Injection site pruritus			
subjects affected / exposed	1 / 106 (0.94%)	2 / 52 (3.85%)	1 / 19 (5.26%)
occurrences (all)	1	2	1
Local swelling			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Thirst			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Feeling abnormal			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Injection site bruising			

subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Enanthema			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Feeling cold			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Feeling hot			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Injection site pain			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Non-cardiac chest pain			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Temperature intolerance			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 106 (0.00%)	4 / 52 (7.69%)	0 / 19 (0.00%)
occurrences (all)	0	4	0
Reproductive system and breast disorders			
Menorrhagia			
subjects affected / exposed	2 / 106 (1.89%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Metrorrhagia			
subjects affected / exposed	0 / 106 (0.00%)	2 / 52 (3.85%)	0 / 19 (0.00%)
occurrences (all)	0	2	0
Amenorrhoea			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Erectile dysfunction			

subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Menstrual disorder			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Pruritus genital			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Scrotal erythema			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Scrotal pain			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	18 / 106 (16.98%)	11 / 52 (21.15%)	5 / 19 (26.32%)
occurrences (all)	19	12	5
Cough			
subjects affected / exposed	9 / 106 (8.49%)	5 / 52 (9.62%)	0 / 19 (0.00%)
occurrences (all)	9	5	0
Oropharyngeal pain			
subjects affected / exposed	7 / 106 (6.60%)	1 / 52 (1.92%)	1 / 19 (5.26%)
occurrences (all)	7	1	1
Dyspnoea exertional			
subjects affected / exposed	5 / 106 (4.72%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	5	0	1
Epistaxis			
subjects affected / exposed	3 / 106 (2.83%)	1 / 52 (1.92%)	1 / 19 (5.26%)
occurrences (all)	3	1	1
Nasal congestion			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	2 / 19 (10.53%)
occurrences (all)	0	1	2
Rhinorrhoea			

subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	1 / 19 (5.26%)
occurrences (all)	1	1	1
Productive cough			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Respiratory tract congestion			
subjects affected / exposed	2 / 106 (1.89%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Sinus congestion			
subjects affected / exposed	2 / 106 (1.89%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	3	0	0
Sneezing			
subjects affected / exposed	2 / 106 (1.89%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Dysphonia			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Hiccups			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Nasal discomfort			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Nasal disorder			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Nasal dryness			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Nasal inflammation			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Nasal mucosal disorder			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Oropharyngeal discomfort			

subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Painful respiration			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Paranasal sinus discomfort			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Pharyngeal oedema			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Rales			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Respiration abnormal			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	22 / 106 (20.75%)	11 / 52 (21.15%)	6 / 19 (31.58%)
occurrences (all)	22	12	6
Depression			
subjects affected / exposed	12 / 106 (11.32%)	8 / 52 (15.38%)	4 / 19 (21.05%)
occurrences (all)	12	8	4
Anxiety			
subjects affected / exposed	6 / 106 (5.66%)	2 / 52 (3.85%)	2 / 19 (10.53%)
occurrences (all)	6	2	2
Depressed mood			
subjects affected / exposed	4 / 106 (3.77%)	2 / 52 (3.85%)	0 / 19 (0.00%)
occurrences (all)	4	2	0
Mood swings			
subjects affected / exposed	2 / 106 (1.89%)	2 / 52 (3.85%)	0 / 19 (0.00%)
occurrences (all)	2	2	0
Affect lability			
subjects affected / exposed	2 / 106 (1.89%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	2	1	0

Agitation			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Anger			
subjects affected / exposed	1 / 106 (0.94%)	2 / 52 (3.85%)	0 / 19 (0.00%)
occurrences (all)	1	2	0
Mood altered			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Sleep disorder			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Apathy			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Drug dependence			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Emotional disorder			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Initial insomnia			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Nervousness			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Restlessness			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Aggression			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Confusional state			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0

Disorientation			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Libido decreased			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Loss of libido			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Personality disorder			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Suicide attempt			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Investigations			
Weight decreased			
subjects affected / exposed	8 / 106 (7.55%)	2 / 52 (3.85%)	2 / 19 (10.53%)
occurrences (all)	8	2	2
Lymphocyte count decreased			
subjects affected / exposed	3 / 106 (2.83%)	1 / 52 (1.92%)	1 / 19 (5.26%)
occurrences (all)	3	1	2
Blood uric acid increased			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Blood pressure increased			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Haemoglobin decreased			
subjects affected / exposed	2 / 106 (1.89%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Platelet count decreased			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	2 / 19 (10.53%)
occurrences (all)	2	0	2
Amylase increased			

subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Blood potassium decreased			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Blood urine present			
subjects affected / exposed	2 / 106 (1.89%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Transaminases increased			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
White blood cell count decreased			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Alanine aminotransferase increased			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Blood calcium decreased			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Blood creatinine increased			

subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Body temperature increased subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Electrocardiogram QT prolonged subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Electrocardiogram ST-T change subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Eosinophil count increased subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 52 (0.00%) 0	1 / 19 (5.26%) 1
Haematocrit decreased subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Haemoglobin increased subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Lipase increased subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	1 / 52 (1.92%) 1	0 / 19 (0.00%) 0
Liver function test abnormal subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Red blood cell count decreased subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Respiratory rate increased subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Injury, poisoning and procedural complications Contusion			

subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Laceration			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Scratch			
subjects affected / exposed	2 / 106 (1.89%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Arthropod bite			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Excoriation			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Procedural pain			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Palpitations			
subjects affected / exposed	3 / 106 (2.83%)	1 / 52 (1.92%)	2 / 19 (10.53%)
occurrences (all)	3	1	2
Tachycardia			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Arrhythmia			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
supraventricular Atrial fibrillation			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Sinus bradycardia			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Supraventricular extrasystoles			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0

Nervous system disorders			
Headache			
subjects affected / exposed	30 / 106 (28.30%)	16 / 52 (30.77%)	5 / 19 (26.32%)
occurrences (all)	30	16	5
Dizziness			
subjects affected / exposed	17 / 106 (16.04%)	6 / 52 (11.54%)	6 / 19 (31.58%)
occurrences (all)	18	8	6
Dysgeusia			
subjects affected / exposed	13 / 106 (12.26%)	2 / 52 (3.85%)	2 / 19 (10.53%)
occurrences (all)	13	2	2
Hypoaesthesia			
subjects affected / exposed	2 / 106 (1.89%)	5 / 52 (9.62%)	0 / 19 (0.00%)
occurrences (all)	4	6	0
Migraine			
subjects affected / exposed	2 / 106 (1.89%)	3 / 52 (5.77%)	1 / 19 (5.26%)
occurrences (all)	2	3	1
Disturbance in attention			
subjects affected / exposed	3 / 106 (2.83%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	3	1	0
Memory impairment			
subjects affected / exposed	3 / 106 (2.83%)	2 / 52 (3.85%)	0 / 19 (0.00%)
occurrences (all)	3	2	0
Hyperaesthesia			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	1 / 19 (5.26%)
occurrences (all)	1	1	1
Paraesthesia			
subjects affected / exposed	2 / 106 (1.89%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	3	1	0
Somnolence			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Lethargy			
subjects affected / exposed	2 / 106 (1.89%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Syncope			

subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Burning sensation			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Carpal tunnel syndrome			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Cognitive disorder			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Dizziness exertional			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Drooling			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Mental impairment			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Neuropathy peripheral			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Parosmia			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	42 / 106 (39.62%)	22 / 52 (42.31%)	10 / 19 (52.63%)
occurrences (all)	46	25	14

Neutropenia			
subjects affected / exposed	5 / 106 (4.72%)	4 / 52 (7.69%)	4 / 19 (21.05%)
occurrences (all)	6	4	5
Leukopenia			
subjects affected / exposed	1 / 106 (0.94%)	2 / 52 (3.85%)	0 / 19 (0.00%)
occurrences (all)	1	2	0
Lymphopenia			
subjects affected / exposed	2 / 106 (1.89%)	1 / 52 (1.92%)	1 / 19 (5.26%)
occurrences (all)	2	1	1
Thrombocytopenia			
subjects affected / exposed	3 / 106 (2.83%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	3	0	1
Lymphadenopathy			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Increased tendency to bruise			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Pancytopenia			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	4 / 106 (3.77%)	2 / 52 (3.85%)	0 / 19 (0.00%)
occurrences (all)	4	2	0
Tinnitus			
subjects affected / exposed	2 / 106 (1.89%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	2	1	0
Ear pruritus			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Ear discomfort			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Ear pain			

subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Hyperacusis subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Hypoacusis subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Otorrhoea subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Eye disorders			
Vision blurred subjects affected / exposed occurrences (all)	8 / 106 (7.55%) 8	2 / 52 (3.85%) 3	3 / 19 (15.79%) 3
Dry eye subjects affected / exposed occurrences (all)	4 / 106 (3.77%) 4	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Eye pruritus subjects affected / exposed occurrences (all)	3 / 106 (2.83%) 3	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Ocular hyperaemia subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Visual impairment subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	2 / 52 (3.85%) 2	0 / 19 (0.00%) 0
Diplopia subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Eye irritation subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	1 / 52 (1.92%) 1	0 / 19 (0.00%) 0
Eye pain subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0

Retinal exudates			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Abnormal sensation in eye			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Conjunctivitis			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Eye haemorrhage			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Eyelid oedema			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Ocular discomfort			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Periorbital oedema			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Retinal haemorrhage			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Retinopathy			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Vitreous floaters			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
photophobia			
subjects affected / exposed	6 / 106 (5.66%)	3 / 52 (5.77%)	0 / 19 (0.00%)
occurrences (all)	6	3	0

Gastrointestinal disorders			
Nausea			
subjects affected / exposed	49 / 106 (46.23%)	19 / 52 (36.54%)	13 / 19 (68.42%)
occurrences (all)	51	22	15
Diarrhoea			
subjects affected / exposed	19 / 106 (17.92%)	6 / 52 (11.54%)	6 / 19 (31.58%)
occurrences (all)	21	6	6
Vomiting			
subjects affected / exposed	17 / 106 (16.04%)	6 / 52 (11.54%)	6 / 19 (31.58%)
occurrences (all)	18	7	6
Anorectal discomfort			
subjects affected / exposed	22 / 106 (20.75%)	9 / 52 (17.31%)	3 / 19 (15.79%)
occurrences (all)	22	9	3
Anal pruritus			
subjects affected / exposed	10 / 106 (9.43%)	8 / 52 (15.38%)	3 / 19 (15.79%)
occurrences (all)	11	10	3
Haemorrhoids			
subjects affected / exposed	8 / 106 (7.55%)	4 / 52 (7.69%)	1 / 19 (5.26%)
occurrences (all)	8	4	1
Dry mouth			
subjects affected / exposed	5 / 106 (4.72%)	3 / 52 (5.77%)	3 / 19 (15.79%)
occurrences (all)	5	3	3
Dyspepsia			
subjects affected / exposed	9 / 106 (8.49%)	2 / 52 (3.85%)	1 / 19 (5.26%)
occurrences (all)	9	2	1
Proctalgia			
subjects affected / exposed	5 / 106 (4.72%)	4 / 52 (7.69%)	0 / 19 (0.00%)
occurrences (all)	5	4	0
Constipation			
subjects affected / exposed	4 / 106 (3.77%)	1 / 52 (1.92%)	3 / 19 (15.79%)
occurrences (all)	4	1	3
Abdominal pain upper			
subjects affected / exposed	3 / 106 (2.83%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	3	0	0
Abdominal pain			

subjects affected / exposed	3 / 106 (2.83%)	2 / 52 (3.85%)	0 / 19 (0.00%)
occurrences (all)	3	2	0
Aphthous stomatitis			
subjects affected / exposed	2 / 106 (1.89%)	2 / 52 (3.85%)	0 / 19 (0.00%)
occurrences (all)	2	2	0
Cheilitis			
subjects affected / exposed	2 / 106 (1.89%)	2 / 52 (3.85%)	0 / 19 (0.00%)
occurrences (all)	2	2	0
Flatulence			
subjects affected / exposed	3 / 106 (2.83%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	3	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Haematochezia			
subjects affected / exposed	2 / 106 (1.89%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	2	1	0
Rectal haemorrhage			
subjects affected / exposed	0 / 106 (0.00%)	2 / 52 (3.85%)	1 / 19 (5.26%)
occurrences (all)	0	2	1
Stomatitis			
subjects affected / exposed	2 / 106 (1.89%)	1 / 52 (1.92%)	1 / 19 (5.26%)
occurrences (all)	2	1	1
Abdominal discomfort			
subjects affected / exposed	3 / 106 (2.83%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	3	0	0
Abdominal distension			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Gingival bleeding			
subjects affected / exposed	2 / 106 (1.89%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Toothache			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	1 / 19 (5.26%)
occurrences (all)	1	1	1
Anal haemorrhage			

subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
Epigastric discomfort			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Glossodynia			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Oral pain			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Proctitis			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Retching			
subjects affected / exposed	2 / 106 (1.89%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	3	0	0
Abdominal pain lower			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Abdominal tenderness			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Anal fissure			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Ascites			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Bowel movement irregularity			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Duodenal ulcer			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Eructation			

subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Faeces pale			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Frequent bowel movements			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal motility disorder			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Gingival pain			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Glossitis			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Haemorrhoidal haemorrhage			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Hyperchlorhydria			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Lip dry			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Lip pain			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Oral discomfort			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Oral disorder			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Perianal erythema			

subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Sensitivity of teeth			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Steatorrhoea			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Swollen tongue			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Tongue coated			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Tongue disorder			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Tooth impacted			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Periportal oedema			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	44 / 106 (41.51%)	17 / 52 (32.69%)	8 / 19 (42.11%)
occurrences (all)	52	18	11
Rash			
subjects affected / exposed	31 / 106 (29.25%)	15 / 52 (28.85%)	9 / 19 (47.37%)
occurrences (all)	38	22	16
Alopecia			

subjects affected / exposed occurrences (all)	13 / 106 (12.26%) 13	11 / 52 (21.15%) 11	4 / 19 (21.05%) 4
Dry skin			
subjects affected / exposed occurrences (all)	11 / 106 (10.38%) 11	11 / 52 (21.15%) 11	6 / 19 (31.58%) 6
Pruritus generalised			
subjects affected / exposed occurrences (all)	4 / 106 (3.77%) 4	3 / 52 (5.77%) 3	3 / 19 (15.79%) 5
Rash maculo-papular			
subjects affected / exposed occurrences (all)	5 / 106 (4.72%) 9	2 / 52 (3.85%) 2	3 / 19 (15.79%) 4
Rash papular			
subjects affected / exposed occurrences (all)	5 / 106 (4.72%) 5	1 / 52 (1.92%) 2	4 / 19 (21.05%) 7
Rash erythematous			
subjects affected / exposed occurrences (all)	4 / 106 (3.77%) 6	1 / 52 (1.92%) 1	2 / 19 (10.53%) 3
Rash pruritic			
subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 2	2 / 52 (3.85%) 4	2 / 19 (10.53%) 3
Dermatitis			
subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	2 / 52 (3.85%) 2	0 / 19 (0.00%) 0
Rash generalised			
subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 2	2 / 52 (3.85%) 2	1 / 19 (5.26%) 1
Swelling face			
subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 2	0 / 52 (0.00%) 0	2 / 19 (10.53%) 2
Erythema			
subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	1 / 52 (1.92%) 1	1 / 19 (5.26%) 1
Night sweats			
subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 2	1 / 52 (1.92%) 1	0 / 19 (0.00%) 0
Psoriasis			

subjects affected / exposed	2 / 106 (1.89%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Eczema			
subjects affected / exposed	2 / 106 (1.89%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	3	1	0
Rash macular			
subjects affected / exposed	2 / 106 (1.89%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	4	1	0
Skin irritation			
subjects affected / exposed	2 / 106 (1.89%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Urticaria			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	1 / 19 (5.26%)
occurrences (all)	1	1	1
Drug eruption			
subjects affected / exposed	2 / 106 (1.89%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Hyperhidrosis			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Blister			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Dermatitis acneiform			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Drug reaction with eosinophilia and systemic symptoms			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Hair growth abnormal			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Hair texture abnormal			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0

Onychoclasia			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Pain of skin			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Photosensitivity reaction			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Purpura			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Rash follicular			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Rash vesicular			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Scab			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Seborrhoea			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Skin burning sensation			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Skin exfoliation			

subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Skin fragility subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Skin lesion subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Stasis dermatitis subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Telangiectasia subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	1 / 52 (1.92%) 1	0 / 19 (0.00%) 0
Renal and urinary disorders Urinary retention subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	1 / 52 (1.92%) 1	0 / 19 (0.00%) 0
Dysuria subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	9 / 106 (8.49%) 12	7 / 52 (13.46%) 7	2 / 19 (10.53%) 3
Myalgia subjects affected / exposed occurrences (all)	6 / 106 (5.66%) 6	7 / 52 (13.46%) 7	0 / 19 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	6 / 106 (5.66%) 6	2 / 52 (3.85%) 2	0 / 19 (0.00%) 0
Muscle spasms			

subjects affected / exposed	3 / 106 (2.83%)	4 / 52 (7.69%)	0 / 19 (0.00%)
occurrences (all)	3	5	0
Pain in extremity			
subjects affected / exposed	2 / 106 (1.89%)	2 / 52 (3.85%)	1 / 19 (5.26%)
occurrences (all)	3	2	2
Joint swelling			
subjects affected / exposed	1 / 106 (0.94%)	2 / 52 (3.85%)	0 / 19 (0.00%)
occurrences (all)	1	2	0
Muscular weakness			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	2 / 19 (10.53%)
occurrences (all)	1	1	2
Musculoskeletal pain			
subjects affected / exposed	2 / 106 (1.89%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	2	1	0
Bone pain			
subjects affected / exposed	2 / 106 (1.89%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Neck pain			
subjects affected / exposed	3 / 106 (2.83%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	4	0	0
Musculoskeletal chest pain			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Costochondritis			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Joint stiffness			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal discomfort			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Plantar fasciitis			

subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Spinal pain			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	5 / 106 (4.72%)	1 / 52 (1.92%)	2 / 19 (10.53%)
occurrences (all)	6	1	3
Nasopharyngitis			
subjects affected / exposed	2 / 106 (1.89%)	1 / 52 (1.92%)	1 / 19 (5.26%)
occurrences (all)	2	1	1
Upper respiratory tract infection			
subjects affected / exposed	0 / 106 (0.00%)	3 / 52 (5.77%)	1 / 19 (5.26%)
occurrences (all)	0	3	1
Cellulitis			
subjects affected / exposed	0 / 106 (0.00%)	3 / 52 (5.77%)	0 / 19 (0.00%)
occurrences (all)	0	3	0
Ear infection			
subjects affected / exposed	1 / 106 (0.94%)	2 / 52 (3.85%)	0 / 19 (0.00%)
occurrences (all)	1	2	0
Oral herpes			
subjects affected / exposed	3 / 106 (2.83%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	3	0	0
Cystitis			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
Influenza			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Pneumonia			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Sinusitis			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0

Skin infection			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Tooth abscess			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Vulvovaginal candidiasis			
subjects affected / exposed	1 / 106 (0.94%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Bronchitis			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Candida infection			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Dermatitis infected			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Folliculitis			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Genital herpes			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Gingivitis			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Herpes pharyngitis			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Parotitis			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Rash pustular			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

Rhinitis			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Scrotal abscess			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Subcutaneous abscess			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Tinea cruris			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	21 / 106 (19.81%)	6 / 52 (11.54%)	4 / 19 (21.05%)
occurrences (all)	21	7	4
Dehydration			
subjects affected / exposed	3 / 106 (2.83%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	3	1	0
Hyponatraemia			
subjects affected / exposed	1 / 106 (0.94%)	0 / 52 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Abnormal loss of weight			
subjects affected / exposed	0 / 106 (0.00%)	1 / 52 (1.92%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Gout			
subjects affected / exposed	0 / 106 (0.00%)	0 / 52 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Hyperuricaemia			

subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	1 / 52 (1.92%) 1	0 / 19 (0.00%) 0
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Hypokalaemia subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0
Hypomagnesaemia subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 52 (0.00%) 0	0 / 19 (0.00%) 0

Non-serious adverse events	Telaprevir 12 Wk +Peg-IFN-alfa- 2a,RBV 48 Wk (Non Randomized)		
Total subjects affected by non-serious adverse events subjects affected / exposed	61 / 62 (98.39%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Melanocytic naevus subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Vascular disorders Pallor subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1		
Circulatory collapse subjects affected / exposed occurrences (all)	2 / 62 (3.23%) 2		
Hot flush subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Hypertension subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		

Hypotension			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Orthostatic hypotension			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Haematoma			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Orthostatic hypertension			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Peripheral coldness			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Vascular pain			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	26 / 62 (41.94%)		
occurrences (all)	29		
Pyrexia			
subjects affected / exposed	15 / 62 (24.19%)		
occurrences (all)	15		
Influenza like illness			
subjects affected / exposed	9 / 62 (14.52%)		
occurrences (all)	9		
Asthenia			
subjects affected / exposed	13 / 62 (20.97%)		
occurrences (all)	16		
Irritability			
subjects affected / exposed	9 / 62 (14.52%)		
occurrences (all)	9		
Chills			

subjects affected / exposed	9 / 62 (14.52%)		
occurrences (all)	9		
Injection site erythema			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	3		
Pain			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	3		
Malaise			
subjects affected / exposed	5 / 62 (8.06%)		
occurrences (all)	5		
Oedema peripheral			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Injection site reaction			
subjects affected / exposed	4 / 62 (6.45%)		
occurrences (all)	4		
Chest pain			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Injection site rash			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Chest discomfort			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Injection site pruritus			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Local swelling			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Thirst			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Feeling abnormal			

subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Injection site bruising subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1		
Enanthema subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1		
Feeling cold subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Feeling hot subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Injection site pain subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Non-cardiac chest pain subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Temperature intolerance subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Reproductive system and breast disorders Menorrhagia subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Metrorrhagia subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Amenorrhoea			

subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Erectile dysfunction			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Menstrual disorder			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Pruritus genital			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Scrotal erythema			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Scrotal pain			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	9 / 62 (14.52%)		
occurrences (all)	13		
Cough			
subjects affected / exposed	9 / 62 (14.52%)		
occurrences (all)	11		
Oropharyngeal pain			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Dyspnoea exertional			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	3		
Epistaxis			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	3		
Nasal congestion			

subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Rhinorrhoea			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Productive cough			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Respiratory tract congestion			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Sinus congestion			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Sneezing			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Dysphonia			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Hiccups			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Nasal discomfort			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Nasal disorder			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Nasal dryness			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Nasal inflammation			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Nasal mucosal disorder			

subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Oropharyngeal discomfort subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1		
Painful respiration subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Paranasal sinus discomfort subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Pharyngeal oedema subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Rales subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Respiration abnormal subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Psychiatric disorders			
Insomnia subjects affected / exposed occurrences (all)	12 / 62 (19.35%) 12		
Depression subjects affected / exposed occurrences (all)	10 / 62 (16.13%) 10		
Anxiety subjects affected / exposed occurrences (all)	3 / 62 (4.84%) 3		
Depressed mood subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Mood swings subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1		

Affect lability			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Agitation			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Anger			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Mood altered			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Sleep disorder			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Apathy			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Drug dependence			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Emotional disorder			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Initial insomnia			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Nervousness			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Restlessness			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Aggression			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		

Confusional state			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Disorientation			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Libido decreased			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Loss of libido			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Personality disorder			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Suicide attempt			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Investigations			
Weight decreased			
subjects affected / exposed	4 / 62 (6.45%)		
occurrences (all)	4		
Lymphocyte count decreased			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Blood uric acid increased			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	3		
Blood pressure increased			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Haemoglobin decreased			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Platelet count decreased			

subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Amylase increased			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Blood potassium decreased			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Blood urine present			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Neutrophil count decreased			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Transaminases increased			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
White blood cell count decreased			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Alanine aminotransferase increased			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Blood calcium decreased			

subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Blood creatinine increased subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1		
Body temperature increased subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Electrocardiogram QT prolonged subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Electrocardiogram ST-T change subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Eosinophil count increased subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Haematocrit decreased subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1		
Haemoglobin increased subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 2		
Lipase increased subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Liver function test abnormal subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Red blood cell count decreased subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1		
Respiratory rate increased subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1		
Injury, poisoning and procedural			

complications			
Contusion			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Laceration			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Scratch			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Arthropod bite			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Excoriation			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Procedural pain			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Palpitations			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Tachycardia			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	3		
Arrhythmia			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
supraventricular Atrial fibrillation			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Sinus bradycardia			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Supraventricular extrasystoles			

subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Nervous system disorders			
Headache			
subjects affected / exposed	17 / 62 (27.42%)		
occurrences (all)	17		
Dizziness			
subjects affected / exposed	14 / 62 (22.58%)		
occurrences (all)	15		
Dysgeusia			
subjects affected / exposed	5 / 62 (8.06%)		
occurrences (all)	5		
Hypoaesthesia			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Migraine			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Disturbance in attention			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Memory impairment			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Hyperaesthesia			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Paraesthesia			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Somnolence			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Lethargy			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		

Syncope			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Burning sensation			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Carpal tunnel syndrome			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Cognitive disorder			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Dizziness exertional			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Droling			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Mental impairment			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Neuropathy peripheral			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Parosmia			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Sciatica			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Tremor			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed occurrences (all)	20 / 62 (32.26%) 23		
Neutropenia subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 2		
Leukopenia subjects affected / exposed occurrences (all)	2 / 62 (3.23%) 2		
Lymphopenia subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1		
Thrombocytopenia subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1		
Lymphadenopathy subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Increased tendency to bruise subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Pancytopenia subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Ear and labyrinth disorders			
Vertigo subjects affected / exposed occurrences (all)	4 / 62 (6.45%) 4		
Tinnitus subjects affected / exposed occurrences (all)	2 / 62 (3.23%) 2		
Ear pruritus subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Ear discomfort subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		

Ear pain			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Hyperacusis			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Hypoacusis			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Otorrhoea			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Eye disorders			
Vision blurred			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Dry eye			
subjects affected / exposed	4 / 62 (6.45%)		
occurrences (all)	4		
Eye pruritus			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Ocular hyperaemia			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Visual impairment			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Diplopia			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Eye irritation			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Eye pain			

subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Retinal exudates			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Abnormal sensation in eye			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Conjunctival haemorrhage			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Eye haemorrhage			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Eyelid oedema			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Ocular discomfort			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Periorbital oedema			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Retinal haemorrhage			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Retinopathy			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Vitreous floaters			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
photophobia			

subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	33 / 62 (53.23%)		
occurrences (all)	37		
Diarrhoea			
subjects affected / exposed	11 / 62 (17.74%)		
occurrences (all)	11		
Vomiting			
subjects affected / exposed	11 / 62 (17.74%)		
occurrences (all)	15		
Anorectal discomfort			
subjects affected / exposed	5 / 62 (8.06%)		
occurrences (all)	5		
Anal pruritus			
subjects affected / exposed	4 / 62 (6.45%)		
occurrences (all)	4		
Haemorrhoids			
subjects affected / exposed	6 / 62 (9.68%)		
occurrences (all)	6		
Dry mouth			
subjects affected / exposed	7 / 62 (11.29%)		
occurrences (all)	7		
Dyspepsia			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	5		
Proctalgia			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	3		
Constipation			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	3		
Abdominal pain upper			
subjects affected / exposed	5 / 62 (8.06%)		
occurrences (all)	6		

Abdominal pain			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Aphthous stomatitis			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Cheilitis			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Flatulence			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Gastrooesophageal reflux disease			
subjects affected / exposed	4 / 62 (6.45%)		
occurrences (all)	4		
Haematochezia			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Rectal haemorrhage			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Stomatitis			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Abdominal discomfort			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Abdominal distension			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Gingival bleeding			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Toothache			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		

Anal haemorrhage			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Epigastric discomfort			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Glossodynia			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Oral pain			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Proctitis			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Retching			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Abdominal pain lower			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Abdominal tenderness			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Anal fissure			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Ascites			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Bowel movement irregularity			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Duodenal ulcer			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		

Eructation			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Faeces pale			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Frequent bowel movements			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Gastrointestinal motility disorder			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Gingival pain			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Glossitis			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Hyperchlorhydria			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Lip dry			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Lip pain			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Oral discomfort			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Oral disorder			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		

Perianal erythema subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Sensitivity of teeth subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Steatorrhoea subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Swollen tongue subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Tongue coated subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Tongue disorder subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1		
Tooth impacted subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Hepatobiliary disorders			
Cholelithiasis subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0		
Periportal oedema subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1		
Skin and subcutaneous tissue disorders			
Pruritus subjects affected / exposed occurrences (all)	24 / 62 (38.71%) 25		
Rash subjects affected / exposed occurrences (all)	13 / 62 (20.97%) 17		
Alopecia			

subjects affected / exposed	7 / 62 (11.29%)		
occurrences (all)	7		
Dry skin			
subjects affected / exposed	4 / 62 (6.45%)		
occurrences (all)	4		
Pruritus generalised			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	3		
Rash maculo-papular			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	4		
Rash papular			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	3		
Rash erythematous			
subjects affected / exposed	4 / 62 (6.45%)		
occurrences (all)	4		
Rash pruritic			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	2		
Dermatitis			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Rash generalised			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Swelling face			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Erythema			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	2		
Night sweats			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Psoriasis			

subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Eczema			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Rash macular			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Skin irritation			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Urticaria			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Drug eruption			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Hyperhidrosis			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Blister			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Dermatitis acneiform			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Drug reaction with eosinophilia and systemic symptoms			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Hair growth abnormal			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Hair texture abnormal			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		

Onychoclasia			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Pain of skin			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Photosensitivity reaction			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Purpura			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Rash follicular			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Rash vesicular			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Scab			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Seborrhoea			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Skin burning sensation			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Skin exfoliation			

<p>subjects affected / exposed occurrences (all)</p> <p>Skin fragility subjects affected / exposed occurrences (all)</p> <p>Skin lesion subjects affected / exposed occurrences (all)</p> <p>Stasis dermatitis subjects affected / exposed occurrences (all)</p> <p>Telangiectasia subjects affected / exposed occurrences (all)</p>	<p>1 / 62 (1.61%) 1</p> <p>0 / 62 (0.00%) 0</p> <p>0 / 62 (0.00%) 0</p> <p>0 / 62 (0.00%) 0</p> <p>0 / 62 (0.00%) 0</p>		
<p>Renal and urinary disorders</p> <p>Urinary retention subjects affected / exposed occurrences (all)</p> <p>Dysuria subjects affected / exposed occurrences (all)</p>	<p>0 / 62 (0.00%) 0</p> <p>1 / 62 (1.61%) 1</p>		
<p>Endocrine disorders</p> <p>Hypothyroidism subjects affected / exposed occurrences (all)</p>	<p>2 / 62 (3.23%) 2</p>		
<p>Musculoskeletal and connective tissue disorders</p> <p>Arthralgia subjects affected / exposed occurrences (all)</p> <p>Myalgia subjects affected / exposed occurrences (all)</p> <p>Back pain subjects affected / exposed occurrences (all)</p> <p>Muscle spasms</p>	<p>8 / 62 (12.90%) 10</p> <p>11 / 62 (17.74%) 12</p> <p>4 / 62 (6.45%) 4</p>		

subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Pain in extremity			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	3		
Joint swelling			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	2		
Muscular weakness			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Musculoskeletal pain			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Bone pain			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Neck pain			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Musculoskeletal chest pain			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Costochondritis			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Joint stiffness			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Musculoskeletal discomfort			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Musculoskeletal stiffness			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Plantar fasciitis			

subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Spinal pain			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	3 / 62 (4.84%)		
occurrences (all)	4		
Nasopharyngitis			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	2		
Upper respiratory tract infection			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Cellulitis			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Ear infection			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Oral herpes			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Cystitis			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Influenza			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Pneumonia			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Sinusitis			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	3		

Skin infection			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Tooth abscess			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Vulvovaginal candidiasis			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Bronchitis			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Candida infection			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Dermatitis infected			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Folliculitis			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Genital herpes			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Gingivitis			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Herpes pharyngitis			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Parotitis			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Rash pustular			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		

Rhinitis			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Scrotal abscess			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Subcutaneous abscess			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Tinea cruris			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Tooth infection			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	10 / 62 (16.13%)		
occurrences (all)	12		
Dehydration			
subjects affected / exposed	2 / 62 (3.23%)		
occurrences (all)	3		
Hyponatraemia			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Abnormal loss of weight			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Gout			
subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Hyperuricaemia			

subjects affected / exposed	0 / 62 (0.00%)		
occurrences (all)	0		
Hypocalcaemia			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Hypokalaemia			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		
Hypomagnesaemia			
subjects affected / exposed	1 / 62 (1.61%)		
occurrences (all)	1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
25 August 2011	Following FDA recommendation, changed study design to randomized study of 2 treatment regimens. Subjects who have rapid viral response (RVR) and no permanent discontinuation of any study drug will be randomized 2:1 to T12/PR12 or T12/PR24 group. To reflect study design changes, title was changed to specify 2 treatment durations and include subjects with prior relapse. Revised the text for sample size and power, to account for the additional treatment arm. Added allowance for 2 interim analyses.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was terminated early at the primary efficacy endpoint (SVR12), by the sponsor on 13 January 2014 due to a decision to modify the drug development plan.

Notes: